Diversigen, Inc. and Alimentiv Inc. Announce Collaboration Agreement for Ulcerative Colitis Research Study

news

In the News

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur ut pellentesque dolor. Nunc vitae turpis eu risus luctus malesuada. Ut id feugiat justo. In ac accumsan lorem. Sed vel imperdiet mauris, a iaculis felis. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Proin vitae ornare libero. Sed arcu est, venenatis ut leo ac, luctus ultrices risus.

Diversigen, Inc. and Alimentiv Inc. Announce Collaboration Agreement for Ulcerative Colitis Research Study

ST. PAUL, Minn., June 25, 2020 (GLOBE NEWSWIRE) — Diversigen, Inc., a subsidiary of OraSure Technologies Inc. (NASDAQ:OSUR), and Alimentiv Inc. (formerly Robarts Clinical Trials) today announced they have signed a collaboration agreement for a research study on patients with Acute Severe Ulcerative Colitis (ASUC).

read more

PRO Development

A patient reported outcome measure, or PRO, may be defined as “any report of the status of a patient’s health condition that comes directly from the patient, without interpretation of the patient’s response by a clinician or anyone else.” These measures are widely used to study chronic diseases and are considered by regulatory agencies such […]

read more

Addressing the Needs of Patients and Regulatory Bodies

Development of Patient-reported Outcome Measures for Ulcerative Colitis and Crohn’s Disease.

read more